HDCT followed by ASCR. Increased dose intensity achieved by double HDCT led to permanent tumor control. We performed double high-dose chemotherapy (HDCT) and autologous stem cell rescue (ASCR) on an 8-yearold girl after relapse of Wilms' tumor with unfavorable Case report histology. Relapse occurred while the patient was still on first-line therapy and showed multiple adverse progAn 8-year-old girl presented with a large mass in the right kidney and two pulmonary metastases. Whole lung irradiation (12 Gy) with local boosts to the Unfavorable histology (UH), original stage IV disease, metastases (20 Gy) was given at the same time as the remission duration of less than 6 months, recurrent disease second postoperative course of chemotherapy. Surgical in an irradiated field in the abdomen and in nonpulmonary removal of pulmonary metastases was performed 4 weeks sites and relapse after initial treatment with more than two after completion of radiotherapy. On microscopic examindrugs predict a significantly worse survival after relapse. 2 ation viable tumor was found. Six months after thoraRecent evidence suggests that high-dose chemotherapy cotomy, while the girl was still on first-line chemotherapy (HDCT) followed by autologous stem cell rescue (ASCR) (11th out of 15 courses), she relapsed with a single pulmonmight be a promising approach in these high-risk ary metastasis. High-dose cyclophosphamide (70 mg/kg by patients. [3][4][5][6] continuous i.v. infusion over 6 h on days 1 and 2, total We report the case of an 8-year-old girl with relapsed dose 140 mg/kg), doxorubicin (25 mg/m 2 by continuous i.v. WT of UH. Salvage treatment was with two courses of infusion over 24 h on days 1-3, total dose 75 mg/m 2 ) and vincristine (1 mg/m 2 by continuous i.v. infusion over 24 h on days 1-3, total dose 3 mg/m 2 ) (HD-CDV) was given and resulted in a partial response. Excision of the pulmonary
ation viable tumor was found. Six months after thoraRecent evidence suggests that high-dose chemotherapy cotomy, while the girl was still on first-line chemotherapy (HDCT) followed by autologous stem cell rescue (ASCR) (11th out of 15 courses), she relapsed with a single pulmonmight be a promising approach in these high-risk ary metastasis. High-dose cyclophosphamide (70 mg/kg by patients. The prognosis in children with recurrent Wilms' tumor of second remission provided an appropriate setting for a unfavorable histology is extremely poor. In a report by second curative approach. As HD-CDV had produced an Grundy et al 2 3-year post-relapse survival was 16 Ϯ 5% unacceptably prolonged period of thrombocytopenia (10 after salvage attempts with conventional multimodal treatweeks), reflecting depleted hematopoietic reserves, a treatment. In relapsed patients, who originally had stage IV disment strategy including the use of ASCR was warranted to ease, the prognosis is even worse. 2 A more aggressive maintain high dose intensity. In order to achieve maximal therapeutic approach might be appropriate in this setting. dose intensification we used a double HDCT regimen with Experience with HDCT followed by ASCR in children with ASCR as salvage treatment. Peripheral blood stem cells recurrent WT and adverse prognostic features is limited, (PBSC) were collected during G-CSF-supported hematopobut promising results have been reported. [3] [4] [5] [6] Responses to ietic recovery after a second course of HD-CDV(15.3 × 10 . Prolonged intensive chemotherapy factor for long-term survival. In our patient, cumulative and partial liver irradiation increased the risk of venobone marrow toxicity from prior treatment had resulted in occlusive disease; therefore, only a 50% dose of etoposide depleted hematopoietic reserves at the time of relapse. (30 mg/kg) was given. 7.5 × 10 8 peripheral blood MNC/kg Second CR was achieved by surgical resection of the pulwere reinfused. To support leukocyte recovery G-CSF thermonary metastasis after only one course of chemotherapy. apy (10 g/kg by continuous i.v. infusion over 12 h until Further use of chemotherapy seemed warranted before white blood cell count Ͼ10 9 /l) was introduced on day +1. starting single HDCT. As it was impossible to achieve an A white blood cell count Ͼ10 9 /l was achieved on day 14. effective dose intensity by a conventional chemotherapeutic Platelet support was still necessary when the second HDCT approach, salvage treatment was given with repeated was started on day +97. Etoposide 20 mg/kg by continuous HDCT and ASCR. i.v. infusion over 2 h was given on days −6 and −5 (total Double HDCT with ASCR has been performed in several dose 40 mg/kg) followed by cyclophosphamide 67 mg/kg malignancies, and has provided positive results in children with advanced neuroblastoma. 9 The evidence suggests that by continuous i.v. infusion over 24 h on days −4, −3, −2 toxicity is high but manageable in experienced centers. (total dose 200 mg/kg). This was followed by the reinfusion Chemotherapeutic agents for HDCT in our patient had to of both 7.5 × 10 8 peripheral blood MNC/kg and 0.5 × 10 8 meet two criteria -efficacy and tolerable toxicity to organs bone marrow MNC/kg. G-CSF therapy was instituted on at risk. day +1, leukocyte counts Ͼ10 9 /l were reached on day 15.
High-dose melphalan, etoposide and carboplatin as sinThrombocytopenia (Ͻ100 × 10 9 /l) persisted for 20 months, gle agents have shown activity in refractory Wilms' tumors. and transfusion-dependent thrombocytopenia for 8 months.
A HDCT regimen with a combination of etoposide, melBoth myeloablative therapies were well tolerated. Acute phalan and carboplatin has been evaluated in 29 patients side-effects were restricted to septicemia, managed with with relapsed WT in a study of Pein et al. 5 With this regiantibiotic therapy. No severe mucositis (ϾWHO II), pneumen all 29 patients were in CR after HDCT, 16 of them monitis, or cardiac complication related to previous total remained in continuous CR after a median follow-up period lung irradiation occurred. There was no further impairment of 19 months. To minimize toxicity of the MEC regimen of renal function, tubular dysfunction (persistent proin our patient with only one remaining kidney and tubular teinuria, glucosuria, phosphaturia) being the sequel of prior dysfunction as a result of prior treatment, the dose of cartreatment. Creatinine clearance remained within the norboplatin was reduced. 8 As partial liver irradiation increased mal range.
the risk of veno-occlusive disease a 50% etoposide dose Radiotherapy of paraortic lymphnodes (30 Gy) was was given. Cyclophosphamide, together with doxorubicin added 6 weeks after the second HDCT. Apart from transient and vincristine, a salvage therapy of relapse, had produced leukocytopenia no side-effects occurred. Four years after a response in our patient. Accordingly, it was reasonable to relapse the girl is in complete second remission and well.
choose cyclophosphamide as a fourth drug combined with Renal tubular dysfunction is the only long-term sequel.
etoposide for second HDCT. Drugs were given in myeloablative doses. Extensive 
